Ginkgo Bioworks Holdings, Inc.
NYSE DNA
Ginkgo Bioworks Holdings, Inc. Goodwill for the quarter ending September 30, 2024: USD 0.00
Ginkgo Bioworks Holdings, Inc. Goodwill is USD 0.00 for the quarter ending September 30, 2024, a -100.00% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.
-
Ginkgo Bioworks Holdings, Inc. Goodwill for the quarter ending September 30, 2023 was USD 58.06 M, a 101.56% change year over year.
-
Ginkgo Bioworks Holdings, Inc. Goodwill for the quarter ending September 30, 2022 was USD 28.80 M, a 72.89% change year over year.
-
Ginkgo Bioworks Holdings, Inc. Goodwill for the quarter ending September 30, 2021 was USD 16.66 M.
Key data
| Date | Goodwill | Total Assets | Current Liabilities | Total Non-Current Liabilities |
|---|
Market news
Loading...
NYSE: DNA
| CEO | Dr. Jason Kelly Ph.D. |
| IPO Date | April 19, 2021 |
| Location | United States |
| Headquarters | 27 Drydock Avenue |
| Employees | 1,218 |
| Sector | Health Care |
| Industries | |
Description
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email